Children's Diabetes Centre, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.
Paediatrics, UWA Medical School, University of Western Australia, Nedlands, Western Australia, Australia.
Diabetes Care. 2024 Oct 1;47(10):1750-1756. doi: 10.2337/dc24-0540.
Continuous glucose monitoring (CGM) can detect early dysglycemia in older children and adults with presymptomatic type 1 diabetes (T1D) and predict risk of progression to clinical onset. However, CGM data for very young children at greatest risk of disease progression are lacking. This study aimed to investigate the use of CGM data measured in children being longitudinally observed in the Australian Environmental Determinants of Islet Autoimmunity (ENDIA) study from birth to age 10 years.
Between January 2021 and June 2023, 31 ENDIA children with persistent multiple islet autoimmunity (PM Ab+) and 24 age-matched control children underwent CGM assessment alongside standard clinical monitoring. The CGM metrics of glucose SD (SDSGL), coefficient of variation (CEV), mean sensor glucose (SGL), and percentage of time >7.8 mmol/L (>140 mg/dL) were determined and examined for between-group differences.
The mean (SD) ages of PM Ab+ and Ab- children were 4.4 (1.8) and 4.7 (1.9) years, respectively. Eighty-six percent of eligible PM Ab+ children consented to CGM wear, achieving a median (quartile 1 [Q1], Q3) sensor wear period of 12.5 (9.0, 15.0) days. PM Ab+ children had higher median (Q1, Q3) SDSGL (1.1 [0.9, 1.3] vs. 0.9 [0.8, 1.0] mmol/L; P < 0.001) and CEV (17.3% [16.0, 20.9] vs. 14.7% [12.9, 16.6]; P < 0.001). Percentage of time >7.8 mmol/L was greater in PM Ab+ children (median [Q1, Q3] 8.0% [4.4, 13.0] compared with 3.3% [1.4, 5.3] in Ab- children; P = 0.005). Mean SGL did not differ significantly between groups (P = 0.10).
CGM is feasible and well tolerated in very young children at risk of T1D. Very young PM Ab+ children have increased SDSGL, CEV, and percentage of time >7.8 mmol/L, consistent with prior studies involving older participants.
连续血糖监测(CGM)可检测到有症状 1 型糖尿病(T1D)前期的儿童和成人的早期糖代谢异常,并预测疾病进展为临床发病的风险。然而,对于疾病进展风险最高的非常年幼的儿童,缺乏 CGM 数据。本研究旨在调查在澳大利亚环境决定胰岛自身免疫(ENDIA)研究中从出生到 10 岁期间进行纵向观察的儿童中使用 CGM 数据的情况。
2021 年 1 月至 2023 年 6 月,31 名持续性多胰岛自身抗体阳性(PM Ab+)的 ENDIA 儿童和 24 名年龄匹配的对照儿童在进行标准临床监测的同时接受 CGM 评估。测定了血糖标准差(SDSGL)、变异系数(CEV)、平均传感器血糖(SGL)和 >7.8mmol/L(>140mg/dL)时间百分比等 CGM 指标,并比较了组间差异。
PM Ab+和 Ab-儿童的平均(标准差)年龄分别为 4.4(1.8)和 4.7(1.9)岁。86%符合条件的 PM Ab+儿童同意佩戴 CGM,中位(四分位 1 [Q1],Q3)传感器佩戴期为 12.5(9.0,15.0)天。PM Ab+儿童的 SDSGL(1.1 [0.9,1.3] vs. 0.9 [0.8,1.0] mmol/L;P<0.001)和 CEV(17.3% [16.0,20.9] vs. 14.7% [12.9,16.6];P<0.001)中位数(Q1,Q3)更高。PM Ab+儿童>7.8mmol/L的时间百分比也更高(中位数[Q1,Q3]8.0% [4.4,13.0]与 Ab-儿童的 3.3% [1.4,5.3];P=0.005)。两组间平均 SGL 无显著差异(P=0.10)。
CGM 在有发生 1 型糖尿病风险的非常年幼的儿童中是可行的,且耐受性良好。非常年幼的 PM Ab+儿童的 SDSGL、CEV 和>7.8mmol/L时间百分比增加,与涉及年长参与者的先前研究一致。